Back to News
Apr 4, 2026 10:16 PM

EXCLUSIVE: FibroBiologics Moves Forward With Human Trial For Diabetic Foot Ulcer Therapy

FibroBiologics Inc. (NASDAQ:FBLG) on Tuesday said it completed manufacturing of the first batch of FibroBiologics' proprietary CYWC628 drug product that will support upcoming first-in-human clinical trials.

Manufactured in accordance with the Food and Drug Administration's (FDA's) Good Manufacturing Practices (CGMP), the drug product will be released after it successfully passes all required safety and quality testing.

CYWC628 Targets Diabetic Foot Ulcers

The CYWC628 fibroblast-based therapy targets diabetic foot ulcers, a condition that affects millions of patients worldwide and currently lacks effective long-term treatment solutions. 

A diabetic foot ulcer is an open sore, typically ...